TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04623164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cocktail from complex phytoadaptogens (CFA)
Description: Cocktail from complex phytoadaptogens (CFA) is composed from 70% alcohol extracts of Glycyrrhiza glabra, Rhodiola rosea, Acantopanax senticosus in the ratio 2:1:1. Application of CFA in 3 group was carried out after non-surgical periodontal therapy (NSPT). After NSPT the patient filled out an Estberg questionnaire to determine the chronotype. After processing the questionnaire, a chronotype was identified and the patient was prescribed CFA dosage. Application of CFA was carried out in the periods of exacerbation of chronic periodontitis within 28 days with a dosage of CFA depending on the chronotype of the person - morning chronotype at 45 drops in the morning before 10.00 o'clock; independent chronotype 20 drops 3 times a day; evening chronotype 30 drops at 14.00 o'clock and 20 drops at 19.00 o'clock.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard non-surgical periodontal treatment (NSPT)
Description: Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard non-surgical periodontal treatment (NSPT)
Description: Oral hygiene instructions (including brushing technique, the use of interdentally flosses, and/or brushes), NSPT (mouth scaling and root planing using an ultrasonic scaler UDS-L LED (Woodpecker, China) and Graceys curettes (Hu Friedy, Chicago, USA)). The treated periodontal pockets were irrigated with 0.12% chlorhexidine gluconate. Patients were given recommendation to rinse their mouth three times daily for 14 days using 0.12% chlorhexidine gluconate
Study: NCT01536639

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
Study: NCT00514267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM 155
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YM 155
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Oral
Study: NCT03668613

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab low dose
Description: dose depends on the weight group

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: secukinumab high dose
Description: dose depends on the weight group
Study: NCT00061568

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood hematopoietic progenitor cell (PBPC) transplant
Description: Peripheral blood hematopoietic progenitor cell (PBPC) transplant
Study: NCT02355132

Intervention type: OTHER
Intervention: Insurance Intervention
Description: Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
Study: NCT02188368

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: POM

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Steroids

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLD

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CFZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BTZ

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CLA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CY
Study: NCT01713868

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Sleep Nursery Education
Description: Nursery-based program for safe sleep

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Sleep Nursery Education
Description: Nursery-based program for safe sleep

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding Nursery Education
Description: Nursery-based program to promote breastfeeding

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding Nursery Education
Description: Nursery-based program to promote breastfeeding

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding Mobile Health Messaging
Description: Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Breastfeeding Mobile Health Messaging
Description: Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Sleep Mobile Health Messaging
Description: Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Safe Sleep Mobile Health Messaging
Description: Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
Study: NCT02020668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Wait list control
Study: NCT03018392

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stryker Tritanium Spinal System
Description: open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
Study: NCT01558700

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sugar pill
Description: Matching capsule given once a day for a total of 17 weeks.
Study: NCT01234129

Intervention type: DRUG
Intervention: zoledronic acid
Description: zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years

Intervention type: DRUG
Intervention: zoledronic acid
Description: zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
Study: NCT02085564

Intervention type: PROCEDURE
Intervention: Peritoneal washing cytology
Description: The methode is describes in the detailed study description
Study: NCT03152318

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rQNestin
Description: rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rQNestin
Description: rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rQNestin
Description: rQNestin is an oncolytic viral vector. It is administered via intratumoral injection during biopsy surgery.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide is an immunomodulating agent. It is administered intravenously in a single dose 2 days (+/- 6 hrs) before surgery.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Description: In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Description: In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stereotactic biopsy
Description: In both arms, subjects will undergo standard of care stereotactic biopsy in the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance to collect the biopsy, and again to administer the rQNestin oncolytic virus.
Study: NCT02659215

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hyalofast
Description: Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Microfracture
Description: Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
Study: NCT04015219

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Self retained cryopreserved amniotic membrane
Description: PROKERA SLIM

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifitegrast ophthalmic solution
Description: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lifitegrast ophthalmic solution
Description: Xiidra® (5% lifitegrast ophthalmic solution, Shire, Lexington, MA)
Study: NCT00061568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral blood hematopoietic progenitor cell Apheresis
Description: Donor-Peripheral blood hematopoietic progenitor cell (PBPC) apheresis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus
Study: NCT04024527

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Proton pump inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: Antibiotic for H. pylori eradication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: Antibiotic for H. pylori eradication
Study: NCT01734421

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: 6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell phone Aplication for Smarth Phone
Study: NCT01042379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Therapy
Description: Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 with or without Trastuzumab
Description: Arm is closed.

Intervention type: DRUG
Group type: OTHER
Intervention: AMG 479 (Ganitumab) plus Metformin
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-2206 with or without Trastuzumab
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 and Trastuzumab
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T-DM1 and Pertuzumab
Description: Arm is closed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab and Trastuzumab
Description: Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganetespib
Description: Arm is closed.

Intervention type: DRUG
Group type: OTHER
Intervention: ABT-888
Description: Arm is closed.

Intervention type: DRUG
Group type: OTHER
Intervention: Neratinib
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PLX3397
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab - 4 cycle
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib plus Irinotecan
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patritumab and Trastuzumab
Description: Arm is closed.
Study: NCT00763659

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega-3-FA
Description: 20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lutein/ Zeaxanthin + Omega-3-FA
Description: 10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0 mg Lutein, Zeaxanthin, Omega-3-FA
Study: NCT03595111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: myocardial biopsy
Description: Myocardial cell edema either focal or diffuse was detected in histopathological examination
Study: NCT00646204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10 mg bid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 2 tabs bid
Study: NCT03394872

Intervention type: PROCEDURE
Intervention: Drainage of the pleural effusion
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab - 8 cycle
Description: Arm is closed.
Study: NCT02348242

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aqueous Gel
Description: 1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyelid Occlusion Dressing
Description: Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Description: 1 drop of Phylarm® artificial tears in the eye every 6 hours

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Artificial Tears
Description: 1 drop of Phylarm® artificial tears in the eye every 6 hours
Study: NCT03490266

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robotic Repair
Description: The surgeon will be utilizing a robotic system to repair the hernia.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Repair
Description: The surgeon will be repairing the hernia laparoscopically.
Study: NCT02880566

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Scalp block
Description: Full scalp block

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Scalp block
Description: Full scalp block
Study: NCT01042379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SGN-LIV1A
Description: Arm is closed. SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab plus Olaparib
Description: Arm is closed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SD-101 + Pembrolizumab
Description: Arm is closed. SD-101: IT injection 2 mg/ml (1 ml for T2 tumors, 2 ml for \>T3 tumors) weekly x 4, then every 3 weeks x 2 cycles 1,2,3,4,7,10 Pembrolizumab: 200mg IV cycles 1,4,7,10 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16; Doxorubicin: 60 mg/m2 IV Every 2 or 3 weeks for 4 cycles; Cyclophosphamide: 600 mg/m2 IV Every 2 or 3 weeks for 4 cycles
Study: NCT01518075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Breathing
Description: Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.~Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non Invasive Mechanical Ventilation
Description: Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
Study: NCT04035785

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kangfu Anti-inflammatory Suppository
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Kangfu Anti-inflammatory Suppository
Description: To evaluate the short-term and long-term efficacy of traditional Chinese medicine of Kangfu anti-inflammatory suppository in reducing the use of antibiotics,reducing the risk of clinical use of drugs.
Study: NCT02611167

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (1 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (3 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (6 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic bone marrow-derived MSCs (10 x 10 6 MSC/kg)
Description: Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
Study: NCT01560624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Treprostinil Diolamine
Description: Active

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04341480

Intervention type: DRUG
Intervention: Chemotherapy
Description: Routine chemotherapy for individual tumor type.
Study: NCT02063997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate 600 mg
Description: Arhalofenate 600 mg tablets once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 mg
Description: Allopurinol 300 mg tablets once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Allopurinol 300 mg
Description: Allopurinol 300 mg tablets once daily for 12 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine 0.6 mg
Description: Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets once daily for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arhalofenate 800 mg
Description: Arhalofenate 800 mg tablets once daily for 12 weeks
Study: NCT03446703

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCIT
Description: SCIT is a 18 weekly sessions lasting 45-60 minutes per session. The group will include 8-12 patients, with 2 therapists. The content of the sessions is based on the Spanish translation of the original SCIT (Social Cognition and Interaction Training) instruction manual (Combs, Adams, et al., 2007); (G. Lahera et al., 2013). The manual of the program developed for the improvement of emotional perception skills, attributional style and theory of mind in people with schizophrenia.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TAR
Description: TAR is a 12-session training on facial affect recognition over a period of 6 weeks. Treatment includes one therapist (psychiatrist or clinical psychologist) and 2 patients. It involves neuropsychological strategies, such as restitution and compensation, as well as principles of errorless learning, direct positive reinforcement, verbalization and self-instruction (Frommann et al., 2003; Wölwer et al., 2005).
Study: NCT01797536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Elbasvir